Ross Leimberg
Director-Back Office Operation at Resilience Biotechnologies, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Kelly | M | 59 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 6 years |
| Deepa Pakianathan | M | 59 |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 4 years |
| David Johnson | M | 59 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 3 years |
| Lee Styslinger | M | 63 |
Harvard Business School
| 12 years |
| Rahul Singhvi | M | 59 |
Resilience Biotechnologies, Inc.
 Resilience Biotechnologies, Inc. BiotechnologyHealth Technology Part of National Resilience, Inc., Resilience Biotechnologies, Inc. operates as a Canadian biotechnology company. The CEO of the company is Rahul Singhvi. | - |
| Lynn Sharp Paine | M | 74 |
Harvard Business School
| 14 years |
| Joseph Fuller | M | 67 |
Harvard Business School
| 12 years |
| Sanford Zweifach | M | 68 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 3 years |
| Regina Hodits | M | 53 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 6 years |
| Briggs Morrison | M | 65 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 4 years |
| Chidozie Ugwumba | M | 41 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 4 years |
| Richard Morris | M | 51 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 3 years |
| Lori Hu | F | 38 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 6 years |
| Safa'a Al-Rais | M | - |
Resilience Biotechnologies, Inc.
Resilience Biotechnologies, Inc. BiotechnologyHealth Technology Part of National Resilience, Inc., Resilience Biotechnologies, Inc. operates as a Canadian biotechnology company. The CEO of the company is Rahul Singhvi. | - |
| Denis Patrick | M | - |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Miles K. Clements | M | - |
Harvard Business School
| 2 years |
| Elizabeth Brillman | F | - |
Harvard Business School
| 2 years |
| Maurice Taylor | M | 38 |
Harvard Business School
| 4 years |
| Momie Qu | F | - |
Harvard Business School
| 2 years |
| Ahmed El-Oraby | M | - |
Harvard Business School
| 2 years |
| Gabe Turner | M | 42 |
Harvard Business School
| 2 years |
| Konstantin von Bismarck | M | - |
Harvard Business School
| 3 years |
| Brij Singh Khurana | M | - |
Harvard Business School
| 2 years |
| Kyle Detwiler | M | 41 |
Harvard Business School
| 2 years |
| Adam Besvinick | M | - |
Harvard Business School
| 2 years |
| Alex Harding | M | - |
Harvard Business School
| 2 years |
| Sorina Casian Botez | F | - |
Harvard Business School
| 2 years |
| Eric Chernoff | M | - |
Harvard Business School
| 2 years |
| Klaus Koenigshausen | M | - |
Harvard Business School
| 2 years |
| Ali Najafbagy | M | - |
Harvard Business School
| 3 years |
| Adam Hasiba | M | 40 |
Harvard Business School
| 2 years |
| Megan Preiner | F | 40 |
Harvard Business School
| 2 years |
| Lucy Zang | F | - |
Harvard Business School
| 2 years |
| Jessica Kramer | F | - |
Harvard Business School
| 2 years |
| Nick Birk | M | - |
Harvard Business School
| 2 years |
| Toufic Khoueiry | M | - |
Harvard Business School
| 2 years |
| Meredith Max Hodges | F | 43 |
Harvard Business School
| 2 years |
| Rohan Ranavat | M | - |
Harvard Business School
| 2 years |
| Tyler Ellis | M | - |
Harvard Business School
| 2 years |
| Tom Musgrave | M | - |
Harvard Business School
| 2 years |
| mark younger | M | - |
Harvard Business School
| 3 years |
| Allen Ruiz | M | - |
Harvard Business School
| 2 years |
| Andrew Puschel | M | - |
Harvard Business School
| 2 years |
| Rebecca Greene | F | - |
Harvard Business School
| 2 years |
| Albert Wang | M | - |
Harvard Business School
| 2 years |
| Katharine Nevins | F | - |
Harvard Business School
| 2 years |
| Nate Kempner | M | - |
Harvard Business School
| 2 years |
| Tara Reeves | F | 42 |
Harvard Business School
| 2 years |
| William Bell | M | - |
Harvard Business School
| 2 years |
| Jonathan Mandelbaum | M | - |
Accelerator Life Science Partners II LP
 Accelerator Life Science Partners II LP Investment ManagersFinance Part of Accelerator Services Corp, Accelerator Life Science Partners II LP functions as a venture capital fund. The company is based in Seattle, WA. | 5 years |
| Nate Lowery | M | - |
Harvard Business School
| 2 years |
| Pankaj Dinodia | M | 39 |
Harvard Business School
| 2 years |
| Jonathan Enav | M | - |
Harvard Business School
| 2 years |
| Andrew Boston | M | - |
Harvard Business School
| 2 years |
| Scott Hofmeister | M | - |
Harvard Business School
| 2 years |
| Melike Abacioglu | F | - |
Harvard Business School
| 2 years |
| Matthew W. Nugent | M | - |
Harvard Business School
| 2 years |
| Louis Beryl | M | - |
Harvard Business School
| 2 years |
| Arvind Navaratnam | M | - |
Harvard Business School
| 2 years |
| Parminder Singh | M | - |
Harvard Business School
| 2 years |
| Erin Arnold | F | - |
Harvard Business School
| 2 years |
| Martha Osier | F | - |
Harvard Business School
| 2 years |
| Rafael E. Romero | M | - |
Harvard Business School
| 2 years |
| Rachel D. Jonas | F | - |
Harvard Business School
| 2 years |
| Patricia Bellinger | F | 63 |
Harvard Business School
| 2 years |
| Melvin Hibberd | M | - |
Harvard Business School
| 2 years |
| Alexander Appel | M | - |
Harvard Business School
| 2 years |
| Eduardo G. Arguello | M | - |
Harvard Business School
| 2 years |
| Tyler D. Gordon | M | - |
Harvard Business School
| 2 years |
| Marques Torbert | M | - |
Harvard Business School
| 2 years |
| Cindy Cheung | F | - |
Harvard Business School
| 2 years |
| Christopher John Kirubi | M | 82 |
Harvard Business School
| - |
| Ruoxi Chen | M | 40 |
Harvard Business School
| 2 years |
| Jonathan Nuger | M | - |
Harvard Business School
| 2 years |
| Shiyan Koh | F | - |
Harvard Business School
| 2 years |
| Anthony Ling | M | - |
Harvard Business School
| 2 years |
| Philip Giampietro | M | - |
Harvard Business School
| 2 years |
| Aymeric Chaumet | M | - |
Harvard Business School
| 4 years |
| Benjamin Leahy Marshall | M | 40 |
Harvard Business School
| 2 years |
| Howard Allan Scott | M | - |
Harvard Business School
| 2 years |
| Emre Demirel | M | - |
Harvard Business School
| 2 years |
| Adam Enbar | M | - |
Harvard Business School
| 2 years |
| T. T. Nguyen Duc | F | - |
Harvard Business School
| 2 years |
| Onusa Chantanapongwanij | M | - |
Harvard Business School
| 2 years |
| Jean Ann Salisbury | F | - |
Harvard Business School
| 2 years |
| Christos Brozos | M | - |
Harvard Business School
| 3 years |
| Lawrence Jeremy Sadaka | M | - |
Harvard Business School
| 2 years |
| Kevin Y. Hwang | M | - |
Harvard Business School
| 2 years |
| Chris Kirk | M | - |
Harvard Business School
| 4 years |
| Matthew Scholder | M | - |
Harvard Business School
| 2 years |
| Matthew Salzberg | M | 40 |
Harvard Business School
| 2 years |
| Magnus Grufman | M | - |
Harvard Business School
| 2 years |
| Chingiz Gadimov | M | - |
Harvard Business School
| 2 years |
| Roy Ben-Dor | M | 41 |
Harvard Business School
| 4 years |
| Peter Saldarriaga | M | 41 |
Harvard Business School
| 2 years |
| Ben D. Levy | M | - |
Harvard Business School
| 2 years |
| Hans Reuter | M | - |
Harvard Business School
| 2 years |
| Brandon Farwell | M | - |
Harvard Business School
| 2 years |
| Aneal Krishnan | M | - |
Harvard Business School
| 2 years |
| Chelsea Burkett | F | - |
Harvard Business School
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 98.00% |
| Canada | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ross Leimberg
- Personal Network
